Calcium silicate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Calcium silicate
Accession Number
DB13829
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
INS NO.552 / INS-552
Categories
UNII
S4255P4G5M
CAS number
1344-95-2
Weight
Average: 230.288
Monoisotopic: 229.9227111
Chemical Formula
CaH6O8Si2
InChI Key
LECAAGVQUHQAJK-UHFFFAOYSA-N
InChI
InChI=1S/Ca.2H3O4Si/c;2*1-5(2,3)4/h;2*1-3H/q+2;2*-1
IUPAC Name
calcium ditrihydrogen silicate
SMILES
[Ca++].O[Si](O)(O)[O-].O[Si](O)(O)[O-]

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be increased when it is combined with Calcium silicate.
2,5-Dimethoxy-4-ethylthioamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when it is combined with Calcium silicate.
4-Bromo-2,5-dimethoxyamphetamineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be increased when it is combined with Calcium silicate.
AbafunginCalcium silicate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcepromazineCalcium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineCalcium silicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetaminophenCalcium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineCalcium silicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetyldigoxinCalcium silicate may increase the arrhythmogenic activities of Acetyldigoxin.
AlbaconazoleCalcium silicate can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
32700984
RxNav
1311526
Wikipedia
Calcium_silicate
ATC Codes
A02AC02 — Calcium silicate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentDental Caries Extending Into Dentin1
2CompletedPreventionAflatoxicosis1
4Not Yet RecruitingTreatmentDeep Carious Lesion / Indirect Pulp Treatment1
Not AvailableCompletedOtherDeep Dental Caries1
Not AvailableCompletedPreventionDental Pulp Capping1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.784 mg/mLALOGPS
logP-0.77ALOGPS
logP-2.6ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)9.82ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.75 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity9.14 m3·mol-1ChemAxon
Polarizability6.06 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal silicates
Direct Parent
Alkaline earth metal silicates
Alternative Parents
Miscellaneous silicates / Metalloid salts / Inorganic oxides / Inorganic calcium salts
Substituents
Silicate / Alkaline earth metal silicate / Inorganic calcium salt / Inorganic oxide / Inorganic salt / Inorganic metalloid salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:49 / Updated on March 01, 2020 21:40

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates